Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in stable …

… Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a
neprilysin (NEP) inhibitor (sacubitril) … place in therapy of sacubitril/valsartan, including future …

… Intuitively, initiation of sacubitril/valsartan may … to sacubitril/valsartan. Supervision by
health care providers to ensure appropriate transition from an ACE inhibitor to sacubitril/valsartan …

… This study aimed to understand stakeholder perspectives on a patient decision aid (PtDA)
meant to help patients with heart failure choose between a generic and relatively low-cost …

… Sacubitril/valsartan is the first of a new class of drugs known as angiotensin receptor … to
receive either sacubitril/valsartan or enalapril. Patients in the sacubitril/valsartan group had a 20…

… Approach to patient selection and initiation of Sacubitril/valsartan in HFrEF: proposed
approach to patient selection, transition from ACE inhibitor, and follow-up for sacubitril/valsartan. …

… with sacubitril/valsartan for targeting preventive measures. … The increased cardiovascular
reporting of sacubitril/valsartan … electrical remodelling induced by sacubitril/valsartan, and calls …

… Expert opinion: Overall, sacubitril-valsartan might be a promising therapeutic approach in …
a tremendous burdening disease from an economic standpoint. The annual cost of care for HF …

… Sacubitril/valsartan reduced the risk of CV … of sacubitril/valsartan in patients with more
advanced CKD are limited. This review discusses the evidence for the role of sacubitril/valsartan in …

… the disease management with a more tailored approach. In such a complex and heterogeneous
… In this viewpoint paper we have reconsidered the role of sacubitril/valsartan (S/V), an …